Hub : Traits :

Schizophrenia (2014)

623 significantly associated models · 165 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	7715776	9571422	2	1	1.9e-08	2.1e-07	7.8e-01	100	RERE
2	1	149880483	150316576	1	1	9.2e-08	1.1e-08	4.2e-02	87	PLEKHO1
3	1	242590540	244359621	3	2	1.8e-10	1.0e-07	1.9e-01	94	CEP170 SDCCAG8
4	2	73631564	74155641	1	1	2.8e-07	1.8e-07	2.2e-01	94	ALMS1P
5	2	197134790	202078494	11	2	2.1e-13	1.1e-11	8.5e-01	100	C2orf47 SF3B1
6	2	233047291	234434621	4	2	8.7e-11	1.2e-13	1.4e-02	89	NGEF
7	3	1442951	3792945	1	1	2.0e-07	3.9e-09	3.1e-04	62	CNTN4
8	3	36235084	37614424	1	1	1.3e-07	5.7e-10	5.7e-04	69	AC011816.1
9	3	51616334	53778875	15	1	4.1e-11	6.3e-10	2.3e-01	96	ITIH4-AS1
10	3	63121945	64546545	1	1	9.1e-10	1.5e-09	1.0e+00	100	THOC7
11	3	135273949	137261517	5	1	1.6e-10	3.4e-11	4.7e-03	82	PCCB
12	3	179627093	181023400	1	1	2.7e-07	2.9e-10	8.3e-05	61	TTC14
13	4	169845720	171339965	1	1	3.7e-08	3.7e-08	1.0e+00	100	CLCN3
14	5	59474215	60936935	1	1	2.0e-10	1.8e-11	2.2e-03	79	ERCC8
15	5	136972187	138474788	2	1	3.9e-11	2.8e-08	1.8e-02	82	FAM53C
16	5	138860604	140337279	1	1	9.3e-08	3.8e-06	3.6e-06	0	CYSTM1
17	6	24300846	24913126	2	1	4.6e-12	3.2e-06	3.0e-01	95	KIAA0319
18	6	43034850	43582584	1	1	2.0e-07	5.3e-07	1.0e+00	100	ZNF318
19	6	84017921	84666980	1	1	1.1e-07	6.9e-08	1.9e-01	94	SNAP91
20	7	1161158	2977732	2	1	4.8e-09	9.4e-13	8.6e-06	61	MAD1L1
21	7	99591418	100979310	1	1	1.2e-07	1.3e-06	3.8e-01	97	GIGYF1
22	7	109603832	111895681	2	1	7.4e-11	4.0e-12	1.1e-03	78	IMMP2L
23	8	8092025	8349757	1	1	1.4e-07	3.2e-07	5.7e-01	99	FLJ10661
24	8	9646560	11045161	1	1	3.1e-07	2.9e-07	6.7e-04	56	RP11-981G7.6
25	8	16409107	17851248	1	1	2.5e-07	3.1e-09	3.9e-04	64	VPS37A
26	8	142839492	144323692	1	1	6.6e-09	7.9e-12	4.1e-07	45	BAI1
27	10	103313599	105647095	12	1	5.3e-17	4.7e-15	4.1e-03	87	AS3MT
28	11	45945837	47632707	4	1	1.4e-09	6.9e-10	3.0e-02	88	ATG13
29	11	63316786	64707978	1	1	3.3e-09	2.1e-05	8.6e-01	100	PPP1R14B
30	12	1204676	2805632	2	1	4.7e-14	1.2e-17	5.3e-05	78	CACNA2D4
31	12	110175537	111634281	2	1	1.7e-08	3.8e-09	4.5e-02	88	VPS29
32	12	122713991	124591385	9	1	1.7e-11	1.7e-11	1.9e-02	88	PITPNM2
33	14	70676661	72273020	1	1	1.8e-09	2.0e-08	9.1e-01	100	PCNX
34	14	103161201	105211221	12	1	3.8e-12	4.9e-12	2.3e-01	97	KLC1
35	15	78135979	79537269	2	1	7.6e-09	3.7e-09	1.0e+00	100	CHRNA5
36	15	83167559	84013521	1	1	3.2e-08	1.2e-07	8.2e-01	100	CPEB1
37	15	84151637	85895721	9	1	1.1e-09	1.7e-08	8.1e-01	100	AC103965.1
38	15	90718541	92135418	2	1	1.7e-13	5.4e-11	8.4e-01	100	FES
39	16	28825605	30823047	7	1	1.3e-08	3.1e-08	6.0e-01	99	MAPK3
40	16	88946761	90172696	2	1	1.6e-08	1.8e-07	4.9e-03	71	CPNE7
41	17	1717695	2453908	1	1	6.9e-08	9.5e-09	2.4e-02	85	SMG6
42	17	17017584	18325085	5	1	1.9e-08	2.6e-08	3.6e-01	97	LRRC48
43	19	18408222	20432930	9	2	1.2e-09	3.1e-09	8.8e-02	92	GMIP SUGP2
44	22	39192995	43232818	13	3	2.1e-10	1.6e-10	2.4e-03	77	MGAT3 NAGA XPNPEP3

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder (2018)	5.7	8	3	6.7	0.99	5.6e-07	AC103965.1 CACNA2D4 ITIH4-AS1 PLEKHO1 PPP1R14B SNAP91 SUGP2 XPNPEP3
Bipolar Disorder or Schizophrenia	14.6	47	33	73.3	0.99	4.3e-39	AC011816.1 AC103965.1 ALMS1P AS3MT ATG13 BAI1 C2orf47 CACNA2D4 CEP170 CHRNA5 CLCN3 CNTN4 CPEB1 CPNE7 CYSTM1 ERCC8 FAM53C FES FLJ10661 GIGYF1 GMIP IMMP2L ITIH4-AS1 KIAA0319 KLC1 LRRC48 MAD1L1 MAPK3 MGAT3 NAGA NGEF PCCB PCNX PITPNM2 PLEKHO1 PPP1R14B RERE RP11-981G7.6 SDCCAG8 SF3B1 SNAP91 SUGP2 THOC7 TTC14 VPS37A XPNPEP3 ZNF318
Depressed Affect (Nagel 2018)	1.8	1	0	0.0	0.00	1.0e+00	CEP170
Depression (Nagel 2018)	1.8	1	0	0.0	0.00	1.0e+00	PCCB
Intelligence (Savage-Jansen 2018)	2.5	8	2	4.4	-0.30	4.7e-01	ALMS1P IMMP2L ITIH4-AS1 KLC1 MGAT3 NAGA NGEF PITPNM2
Neuroticism (Nagel 2018)	2.2	4	1	2.2	0.73	2.7e-01	AS3MT PCCB RERE SUGP2
Schizophrenia (2018)	14.7	48	30	66.7	1.00	9.5e-50	AC011816.1 AC103965.1 ALMS1P AS3MT ATG13 BAI1 C2orf47 CACNA2D4 CEP170 CHRNA5 CLCN3 CNTN4 CPEB1 CPNE7 CYSTM1 ERCC8 FAM53C FES FLJ10661 GIGYF1 GMIP IMMP2L ITIH4-AS1 KIAA0319 KLC1 LRRC48 MAD1L1 MAPK3 MGAT3 NAGA NGEF PCCB PCNX PITPNM2 PLEKHO1 PPP1R14B RERE RP11-981G7.6 SDCCAG8 SF3B1 SMG6 SNAP91 SUGP2 THOC7 TTC14 VPS29 XPNPEP3 ZNF318
Schizophrenia vs Biploar Disorder	3.5	2	0	0.0	0.00	1.0e+00	ATG13 VPS29
Worry (Nagel 2018)	3.1	8	3	6.7	0.99	7.4e-06	AS3MT C2orf47 ITIH4-AS1 MAPK3 PCCB SUGP2 THOC7 XPNPEP3
Alzheimer’s Disease (including proxy)	1.4	1	0	0.0	0.00	1.0e+00	CYSTM1
Crohns Disease (2017)	1.2	2	0	0.0	0.00	1.0e+00	GIGYF1 SF3B1
Irritable Bowel Disease (IBD)	1.2	1	1	2.2	0.00	1.0e+00	GIGYF1
Reaction Time	2.8	6	0	0.0	1.00	2.5e-06	ATG13 C2orf47 IMMP2L NGEF RERE SNAP91
Verbal and Numeric Reasoning (VNR)	2.7	4	1	2.2	-0.99	1.2e-02	ALMS1P ITIH4-AS1 MGAT3 NAGA
Breast Cancer	2.0	3	1	2.2	0.00	1.0e+00	FES LRRC48 SUGP2
Bipolar Disorder (2011)	5.1	3	0	0.0	0.00	1.0e+00	CACNA2D4 ITIH4-AS1 SNAP91
Coronary Artery Disease (CAD)	1.9	3	0	0.0	0.00	1.0e+00	AS3MT LRRC48 SMG6
Crohns Disease (2012)	1.3	1	0	0.0	0.00	1.0e+00	SF3B1
Lupus	1.4	1	0	0.0	0.00	1.0e+00	FLJ10661
Neuroticism (2016)	2.3	3	1	2.2	0.00	1.0e+00	FLJ10661 RP11-981G7.6 THOC7
Blood Eosinophil Count	1.3	11	7	15.6	-0.16	6.3e-01	AC103965.1 GIGYF1 GMIP ITIH4-AS1 LRRC48 MAPK3 PITPNM2 RERE SF3B1 SUGP2 XPNPEP3
Blood Platelet Count	1.7	12	7	15.6	-0.11	7.5e-01	AC011816.1 AC103965.1 AS3MT GMIP ITIH4-AS1 KIAA0319 NGEF PCCB PITPNM2 SF3B1 SMG6 SUGP2
Blood Red Count	1.5	13	6	13.3	0.17	5.7e-01	AC103965.1 AS3MT C2orf47 GIGYF1 ITIH4-AS1 KLC1 LRRC48 MAPK3 PITPNM2 SF3B1 SMG6 SUGP2 VPS29
Blood White Count	1.4	10	9	20.0	0.41	2.4e-01	FES KLC1 LRRC48 MAPK3 MGAT3 NAGA PCCB RERE SMG6 THOC7
Heel T-Score	3.0	10	7	15.6	-0.06	8.6e-01	AC103965.1 ALMS1P ATG13 KLC1 MAPK3 NGEF PITPNM2 PLEKHO1 RERE SMG6
BMI	2.3	10	6	13.3	-0.60	6.6e-02	AS3MT BAI1 C2orf47 CPNE7 ITIH4-AS1 KLC1 MAPK3 SMG6 TTC14 VPS29
Height	1.6	14	11	24.4	-0.03	9.3e-01	AC103965.1 AS3MT CEP170 FES ITIH4-AS1 KLC1 LRRC48 MAPK3 MGAT3 NGEF PITPNM2 SDCCAG8 SUGP2 THOC7
Waist Hip Ratio (WHR)	2.2	11	5	11.1	0.12	7.4e-01	AC103965.1 ERCC8 FAM53C ITIH4-AS1 LRRC48 MGAT3 PCCB PCNX PITPNM2 SF3B1 SMG6
Systolic Blood Pressure	3.0	10	6	13.3	0.07	8.4e-01	AS3MT C2orf47 FES LRRC48 PCNX PPP1R14B RERE SDCCAG8 TTC14 VPS29
Smoking Status	2.7	6	1	2.2	-0.29	5.8e-01	AS3MT ERCC8 FES KLC1 RERE SNAP91
Allergy or Eczema	2.3	4	2	4.4	-0.31	6.9e-01	LRRC48 PITPNM2 RERE SF3B1
Cardiovascular Disease	2.7	7	3	6.7	-0.32	4.9e-01	AS3MT ATG13 FES KLC1 PCCB PCNX SDCCAG8
Hypothyroidism (self reported)	1.2	1	1	2.2	0.00	1.0e+00	GIGYF1
Respiratory disease	1.5	1	1	2.2	0.00	1.0e+00	RERE
Lung FEV1/FVC ratio	1.9	7	3	6.7	-0.12	7.9e-01	AC103965.1 CHRNA5 ITIH4-AS1 LRRC48 MAPK3 RERE SMG6
Lung FVC	1.3	6	3	6.7	-0.55	2.5e-01	CHRNA5 CPNE7 LRRC48 MAD1L1 PITPNM2 PLEKHO1
Neuroticism	1.9	3	2	4.4	0.00	1.0e+00	AS3MT PCCB RERE
Chronotype (morning person)	1.5	1	0	0.0	0.00	1.0e+00	SF3B1
Hair Pigment	1.4	10	7	15.6	-0.51	1.3e-01	CPEB1 CPNE7 FAM53C FES GIGYF1 KLC1 PCNX PITPNM2 PLEKHO1 XPNPEP3
Tanning	2.4	3	1	2.2	0.00	1.0e+00	CPNE7 ERCC8 ITIH4-AS1
Hand grip strength (left)	1.4	4	0	0.0	0.34	6.6e-01	AS3MT FES MAPK3 SNAP91
Number of treatments/medications taken	1.5	1	0	0.0	0.00	1.0e+00	FES
Sensitivity / hurt feelings	2.3	3	2	4.4	0.00	1.0e+00	FES FLJ10661 SUGP2
Relative age of first facial hair	1.3	1	0	0.0	0.00	1.0e+00	CEP170
Systolic blood pressure, automated reading	3.2	6	5	11.1	0.27	6.1e-01	AS3MT FES FLJ10661 PPP1R14B RERE RP11-981G7.6
Angina	1.7	1	1	2.2	0.00	1.0e+00	FES
Pack years adult smoking proportion	4.9	2	1	2.2	0.00	1.0e+00	CHRNA5 KLC1
Impedance of leg (right)	3.6	15	10	22.2	0.19	5.0e-01	AC103965.1 AS3MT C2orf47 ERCC8 FES FLJ10661 ITIH4-AS1 KLC1 LRRC48 MAPK3 NGEF RP11-981G7.6 SF3B1 SMG6 SUGP2
Leg fat-free mass (left)	2.4	12	6	13.3	-0.33	3.0e-01	AS3MT C2orf47 CEP170 ERCC8 FES FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SMG6 VPS29
Trunk fat percentage	1.6	5	3	6.7	0.24	6.9e-01	AC103965.1 CPNE7 MAPK3 RERE SF3B1
Current tobacco smoking	2.4	4	0	0.0	0.42	5.8e-01	AS3MT CHRNA5 KLC1 RP11-981G7.6
Maternal smoking around birth	2.3	3	1	2.2	0.00	1.0e+00	AS3MT CHRNA5 KLC1
Fed-up feelings	2.5	2	1	2.2	0.00	1.0e+00	FLJ10661 PCCB
Relative age voice broke	1.2	1	0	0.0	0.00	1.0e+00	PCCB
Taking other prescription medications	1.5	1	0	0.0	0.00	1.0e+00	CPNE7
Age when periods started (menarche)	1.6	1	1	2.2	0.00	1.0e+00	MAPK3
Heel bone mineral density (BMD) T-score, automated (left)	3.4	5	4	8.9	0.16	8.0e-01	FLJ10661 NGEF RERE RP11-981G7.6 SMG6
High blood pressure	3.4	7	3	6.7	-0.53	2.3e-01	FES FLJ10661 PCCB PCNX RP11-981G7.6 SDCCAG8 SMG6
Hayfever, allergic rhinitis or eczema	1.9	3	2	4.4	0.00	1.0e+00	PITPNM2 RERE SF3B1
Multivitamins +/- minerals	1.7	1	0	0.0	0.00	1.0e+00	BAI1
Stomach or abdominal pain in last month	2.0	1	0	0.0	0.00	1.0e+00	GIGYF1
Medication: Atenolol	2.2	1	1	2.2	0.00	1.0e+00	FES
Medication: Levothyroxine sodium	1.5	2	1	2.2	0.00	1.0e+00	FLJ10661 GIGYF1
Sitting height	1.9	7	3	6.7	0.19	6.6e-01	AC103965.1 FAM53C MGAT3 NGEF PITPNM2 SUGP2 THOC7
Chronic bronchitis/emphysema (father)	2.4	1	1	2.2	0.00	1.0e+00	CHRNA5
High blood pressure (mother)	3.0	1	1	2.2	0.00	1.0e+00	FES
Body mass index (BMI)	2.5	10	4	8.9	-0.40	2.6e-01	AS3MT BAI1 C2orf47 FLJ10661 ITIH4-AS1 KLC1 MAPK3 RP11-981G7.6 SMG6 VPS29
Impedance of leg (left)	3.6	13	10	22.2	0.17	5.7e-01	AC103965.1 AS3MT ERCC8 FES FLJ10661 ITIH4-AS1 LRRC48 MAPK3 NGEF RP11-981G7.6 SF3B1 SMG6 SUGP2
Leg predicted mass (left)	2.4	12	6	13.3	-0.33	2.9e-01	AS3MT C2orf47 CEP170 ERCC8 FES FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SMG6 VPS29
Trunk fat mass	1.9	5	3	6.7	-0.78	1.2e-01	AC103965.1 AS3MT C2orf47 CPNE7 MAPK3
Waist circumference	2.2	6	1	2.2	-0.88	1.9e-02	AS3MT BAI1 C2orf47 MAPK3 PCCB SMG6
Number of incorrect matches in round	2.7	3	1	2.2	0.00	1.0e+00	AS3MT FES MAPK3
Past tobacco smoking	2.2	1	1	2.2	0.00	1.0e+00	AS3MT
Alcohol usually taken with meals	1.6	2	0	0.0	0.00	1.0e+00	ERCC8 FES
Nervous feelings	3.4	6	5	11.1	0.42	4.0e-01	AS3MT FLJ10661 ITIH4-AS1 MAPK3 PCCB RP11-981G7.6
Frequency of tenseness / restlessness in last 2 weeks	2.0	1	0	0.0	0.00	1.0e+00	PCCB
Hearing difficulty/problems with background noise	1.9	3	0	0.0	0.00	1.0e+00	KLC1 SNAP91 ZNF318
Forced vital capacity (FVC)	1.3	4	1	2.2	-0.69	3.1e-01	AC103965.1 CEP170 CHRNA5 PLEKHO1
Heel bone mineral density (BMD) T-score, automated (right)	3.3	6	4	8.9	0.06	9.1e-01	FLJ10661 KIAA0319 NGEF RERE RP11-981G7.6 SMG6
Qualifications: None of the above	1.8	3	1	2.2	0.00	1.0e+00	ALMS1P ERCC8 PITPNM2
Financial difficulties in last 2 years	1.1	1	0	0.0	0.00	1.0e+00	KLC1
Mouth/teeth dental problems	1.8	1	0	0.0	0.00	1.0e+00	KLC1
Heart attack	2.0	1	1	2.2	0.00	1.0e+00	FES
Allergy	1.8	4	3	6.7	0.21	7.9e-01	FES PITPNM2 RERE SF3B1
Hayfever/allergic rhinitis (self-reported)	1.5	1	0	0.0	0.00	1.0e+00	SF3B1
Medication: Ramipril	1.9	1	0	0.0	0.00	1.0e+00	FES
Medication: Simvastatin	1.6	1	1	2.2	0.00	1.0e+00	FES
Fluid intelligence score	2.2	3	1	2.2	0.00	1.0e+00	ALMS1P MGAT3 PITPNM2
Illnesses of siblings	1.6	1	1	2.2	0.00	1.0e+00	FES
Neuroticism score	2.8	3	3	6.7	0.00	1.0e+00	FLJ10661 PCCB RP11-981G7.6
Weight	2.3	9	3	6.7	-0.49	1.8e-01	AC103965.1 AS3MT C2orf47 FLJ10661 MAPK3 NGEF PITPNM2 SMG6 VPS29
Impedance of arm (right)	3.3	12	7	15.6	0.39	2.1e-01	AC103965.1 ERCC8 FAM53C FLJ10661 ITIH4-AS1 MAPK3 RP11-981G7.6 SF3B1 SMG6 SNAP91 SUGP2 VPS29
Arm fat percentage (right)	1.8	7	3	6.7	0.05	9.2e-01	AS3MT C2orf47 CPNE7 FLJ10661 KLC1 MAPK3 SF3B1
Trunk fat-free mass	2.3	11	7	15.6	-0.37	2.6e-01	AS3MT ERCC8 FAM53C MAPK3 MGAT3 NAGA NGEF PITPNM2 SF3B1 SMG6 VPS29
Hip circumference	2.3	9	3	6.7	-0.59	9.3e-02	AC103965.1 AS3MT BAI1 ERCC8 FLJ10661 ITIH4-AS1 MAPK3 PITPNM2 VPS29
Alcohol intake versus 10 years previously	1.5	1	0	0.0	0.00	1.0e+00	MAPK3
Father's age at death	2.2	2	2	4.4	0.00	1.0e+00	CHRNA5 FES
Worrier / anxious feelings	3.9	7	5	11.1	0.39	3.9e-01	AS3MT C2orf47 CACNA2D4 FLJ10661 ITIH4-AS1 PCCB RP11-981G7.6
Frequency of tiredness / lethargy in last 2 weeks	1.6	1	0	0.0	0.00	1.0e+00	KLC1
Forced expiratory volume in 1-second (FEV1)	1.8	5	3	6.7	-0.77	1.2e-01	AC103965.1 CEP170 CHRNA5 FLJ10661 PLEKHO1
Pulse rate	2.9	3	1	2.2	0.00	1.0e+00	GIGYF1 ITIH4-AS1 LRRC48
Qualifications: A levels/AS levels or equivalent	2.2	4	1	2.2	-0.36	6.4e-01	ALMS1P ERCC8 MGAT3 PITPNM2
Mouth/teeth dental problems: Dentures	2.4	2	0	0.0	0.00	1.0e+00	CHRNA5 FLJ10661
Asthma	1.5	1	0	0.0	0.00	1.0e+00	RERE
Medication: Cholesterol lowering	1.7	1	1	2.2	0.00	1.0e+00	FES
Lung cancer (father)	2.0	1	1	2.2	0.00	1.0e+00	CHRNA5
Illnesses of mother	1.5	1	1	2.2	0.00	1.0e+00	FES
Forced expiratory volume in 1-second (FEV1), Best measure	1.7	4	2	4.4	-0.72	2.8e-01	AC103965.1 CEP170 CHRNA5 PLEKHO1
Impedance of arm (left)	3.2	13	7	15.6	0.34	2.5e-01	AC103965.1 AS3MT ERCC8 FLJ10661 ITIH4-AS1 MAPK3 NAGA RP11-981G7.6 SF3B1 SMG6 SNAP91 SUGP2 VPS29
Arm fat mass (right)	2.1	8	2	4.4	-0.39	3.4e-01	AS3MT BAI1 C2orf47 CPNE7 FLJ10661 KLC1 MAPK3 VPS29
Trunk predicted mass	2.3	11	7	15.6	-0.37	2.6e-01	AS3MT ERCC8 FAM53C MAPK3 MGAT3 NAGA NGEF PITPNM2 SF3B1 SMG6 VPS29
Standing height	1.6	11	4	8.9	-0.16	6.3e-01	AC103965.1 AS3MT CEP170 FLJ10661 ITIH4-AS1 KLC1 MAPK3 MGAT3 NGEF PITPNM2 SDCCAG8
Breastfed as a baby	1.8	1	0	0.0	0.00	1.0e+00	PITPNM2
Tense / 'highly strung'	2.7	5	1	2.2	0.22	7.2e-01	CACNA2D4 FLJ10661 MAPK3 PCCB RERE
Birth weight of first child	1.9	2	1	2.2	0.00	1.0e+00	AS3MT FES
Peak expiratory flow (PEF)	1.6	2	0	0.0	0.00	1.0e+00	FLJ10661 RP11-981G7.6
Qualifications: O levels/GCSEs or equivalent	1.8	2	0	0.0	0.00	1.0e+00	ALMS1P PITPNM2
Mouth/teeth dental problems: Bleeding gums	1.7	1	0	0.0	0.00	1.0e+00	RP11-981G7.6
Medication: Paracetamol	2.2	1	0	0.0	0.00	1.0e+00	SDCCAG8
Headache pain in last month	2.2	2	2	4.4	0.00	1.0e+00	CEP170 SDCCAG8
Medication for cholesterol, blood pressure or diabetes	2.5	1	1	2.2	0.00	1.0e+00	FES
Hypothyroidism/myxoedema (self-reported)	1.8	3	2	4.4	0.00	1.0e+00	FLJ10661 GIGYF1 RP11-981G7.6
Medication: Amlodipine	1.7	1	1	2.2	0.00	1.0e+00	FES
Birth weight	1.4	2	1	2.2	0.00	1.0e+00	AS3MT FES
Chronic bronchitis/emphysema (mother)	1.7	1	1	2.2	0.00	1.0e+00	CHRNA5
High blood pressure (siblings)	1.9	2	1	2.2	0.00	1.0e+00	FES SMG6
Forced vital capacity (FVC), Best measure	1.1	3	1	2.2	0.00	1.0e+00	AC103965.1 CEP170 PLEKHO1
Body fat percentage	1.6	5	2	4.4	0.26	6.7e-01	AC103965.1 CPNE7 MAPK3 RERE SF3B1
Leg fat percentage (right)	1.6	3	1	2.2	0.00	1.0e+00	AC103965.1 MAPK3 RERE
Arm fat-free mass (right)	2.5	11	8	17.8	-0.43	1.9e-01	AS3MT ERCC8 FAM53C FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SF3B1 SMG6 VPS29
Comparative body size at age 10	2.3	6	2	4.4	-0.65	1.6e-01	ERCC8 FLJ10661 MAPK3 SMG6 SUGP2 VPS37A
Worry too long after embarrassment	2.0	2	2	4.4	0.00	1.0e+00	FLJ10661 PCCB
Wheeze or whistling in the chest in last year	1.8	3	0	0.0	0.00	1.0e+00	ATG13 MAPK3 RERE
Qualifications: College or University degree	2.2	7	4	8.9	0.10	8.3e-01	ALMS1P CEP170 ERCC8 KLC1 MGAT3 NGEF PITPNM2
Medication for pain relief, constipation, heartburn	1.9	2	0	0.0	0.00	1.0e+00	PCNX SDCCAG8
Medication: Blood pressure	2.7	1	1	2.2	0.00	1.0e+00	FES
Angina (self-reported)	1.7	1	1	2.2	0.00	1.0e+00	FES
Mean time to correctly identify matches	2.8	4	0	0.0	1.00	6.7e-04	ATG13 IMMP2L RERE SNAP91
Whole body fat mass	2.0	5	3	6.7	-0.74	1.5e-01	AC103965.1 AS3MT C2orf47 FLJ10661 MAPK3
Leg fat mass (right)	2.0	7	3	6.7	-0.50	2.5e-01	AC103965.1 AS3MT FLJ10661 ITIH4-AS1 MAPK3 RP11-981G7.6 VPS29
Arm predicted mass (right)	2.5	11	7	15.6	-0.42	1.9e-01	AS3MT ERCC8 FAM53C FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SF3B1 SMG6 VPS29
Pulse rate, automated reading	3.4	5	2	4.4	0.81	9.4e-02	AC103965.1 GIGYF1 ITIH4-AS1 LRRC48 VPS29
Alcohol intake frequency.	1.5	4	0	0.0	-0.60	4.0e-01	BAI1 CHRNA5 MAPK3 PITPNM2
Comparative height size at age 10	1.9	7	4	8.9	0.20	6.7e-01	AC103965.1 FES ITIH4-AS1 KLC1 MAPK3 NGEF PITPNM2
Suffer from 'nerves'	2.4	2	1	2.2	0.00	1.0e+00	AS3MT FLJ10661
Overall health rating	1.9	4	0	0.0	0.53	4.7e-01	CPNE7 KLC1 LRRC48 SF3B1
Medication: Aspirin	1.7	1	1	2.2	0.00	1.0e+00	FES
Hypertension (Self-reported)	3.4	6	3	6.7	-0.48	3.3e-01	FES FLJ10661 PCCB PPP1R14B RP11-981G7.6 SMG6
Illnesses of father: Heart disease	2.2	2	2	4.4	0.00	1.0e+00	FES SMG6
Smoking status: Previous	1.9	1	0	0.0	0.00	1.0e+00	KIAA0319
Forced expiratory volume in 1-second (FEV1), predicted	1.4	1	1	2.2	0.00	1.0e+00	AC103965.1
Whole body fat-free mass	2.4	11	6	13.3	-0.40	2.2e-01	AS3MT CEP170 ERCC8 FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SF3B1 SMG6 VPS29
Leg fat-free mass (right)	2.4	12	6	13.3	-0.33	2.9e-01	AS3MT C2orf47 CEP170 ERCC8 FES FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SMG6 VPS29
Arm fat percentage (left)	1.8	8	1	2.2	0.12	7.8e-01	AS3MT C2orf47 CPNE7 FLJ10661 KLC1 MAPK3 RERE SF3B1
Average weekly red wine intake	1.3	1	0	0.0	0.00	1.0e+00	PITPNM2
Mood swings	1.8	1	0	0.0	0.00	1.0e+00	FLJ10661
Loneliness, isolation	1.2	1	0	0.0	0.00	1.0e+00	RERE
Long-standing illness, disability or infirmity	1.9	1	0	0.0	0.00	1.0e+00	KLC1
Qualifications: nursing, teaching	1.8	3	0	0.0	0.00	1.0e+00	ALMS1P ERCC8 PITPNM2
Medication for cholesterol	1.6	1	0	0.0	0.00	1.0e+00	FES
Asthma (self-reported)	1.5	1	0	0.0	0.00	1.0e+00	RERE
Medication: Aspirin	1.9	1	1	2.2	0.00	1.0e+00	FES
Illnesses of father: None of the above (group 1)	2.2	1	1	2.2	0.00	1.0e+00	FES
Smoking status: Current	2.3	2	0	0.0	0.00	1.0e+00	AS3MT KLC1
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.6	3	1	2.2	0.00	1.0e+00	CHRNA5 MAPK3 PLEKHO1
Whole body water mass	2.4	11	7	15.6	-0.40	2.2e-01	AS3MT CEP170 ERCC8 FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SF3B1 SMG6 VPS29
Leg predicted mass (right)	2.4	12	6	13.3	-0.33	3.0e-01	AS3MT C2orf47 CEP170 ERCC8 FES FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SMG6 VPS29
Arm fat mass (left)	2.2	8	3	6.7	-0.41	3.1e-01	AS3MT BAI1 C2orf47 CPNE7 FLJ10661 KLC1 MAPK3 VPS29
Number of self-reported non-cancer illnesses	1.6	1	0	0.0	0.00	1.0e+00	LRRC48
Average weekly champagne plus white wine intake	1.7	1	0	0.0	0.00	1.0e+00	RERE
Miserableness	2.1	3	1	2.2	0.00	1.0e+00	CEP170 FLJ10661 RP11-981G7.6
Guilty feelings	2.2	2	0	0.0	0.00	1.0e+00	FLJ10661 KIAA0319
Hearing aid user	1.6	1	0	0.0	0.00	1.0e+00	ERCC8
Medication: Blood pressure	2.6	3	1	2.2	0.00	1.0e+00	CPNE7 FES RP11-981G7.6
Medication: Bendroflumethiazide	2.1	3	1	2.2	0.00	1.0e+00	FES FLJ10661 RP11-981G7.6
Illnesses of father: High blood pressure	2.5	1	1	2.2	0.00	1.0e+00	FES
Ever smoked	2.1	1	0	0.0	0.00	1.0e+00	AS3MT
Basal metabolic rate	2.4	12	5	11.1	-0.46	1.3e-01	AS3MT C2orf47 CEP170 ERCC8 FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SF3B1 SMG6 VPS29
Leg fat percentage (left)	1.7	3	1	2.2	0.00	1.0e+00	FLJ10661 MAPK3 RERE
Arm fat-free mass (left)	2.5	10	6	13.3	-0.41	2.3e-01	AS3MT ERCC8 FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SF3B1 SMG6 VPS29
Number of operations (self-reported)	1.7	1	0	0.0	0.00	1.0e+00	ERCC8
Average weekly beer plus cider intake	1.4	1	0	0.0	0.00	1.0e+00	FLJ10661
Irritability	2.7	2	2	4.4	0.00	1.0e+00	FLJ10661 RP11-981G7.6
Risk taking	3.3	3	1	2.2	0.00	1.0e+00	CEP170 KLC1 PCCB
Diastolic blood pressure, automated reading	4.1	10	8	17.8	-0.14	6.9e-01	ALMS1P CEP170 FES FLJ10661 GIGYF1 NAGA PITPNM2 RERE RP11-981G7.6 SDCCAG8
Unable to work because of sickness or disability	2.0	1	0	0.0	0.00	1.0e+00	SF3B1
Vascular/heart problems diagnosed by doctor	3.6	8	1	2.2	0.37	3.7e-01	AS3MT FES FLJ10661 PCCB PCNX PPP1R14B RP11-981G7.6 SMG6
Pain experienced in last month	1.2	1	0	0.0	0.00	1.0e+00	LRRC48
Heart attack/myocardial infarction (self-reported)	1.9	1	1	2.2	0.00	1.0e+00	FES
Heart disease (siblings)	1.4	1	0	0.0	0.00	1.0e+00	FES
Pack years of smoking	4.4	1	1	2.2	0.00	1.0e+00	CHRNA5
Impedance of whole body	3.7	13	10	22.2	0.43	1.4e-01	AC103965.1 AS3MT CACNA2D4 ERCC8 FLJ10661 ITIH4-AS1 MAPK3 RERE RP11-981G7.6 SF3B1 SMG6 SUGP2 VPS29
Leg fat mass (left)	2.1	6	3	6.7	-0.78	6.6e-02	AS3MT C2orf47 FLJ10661 ITIH4-AS1 MAPK3 VPS29
Arm predicted mass (left)	2.5	10	5	11.1	-0.43	2.2e-01	AS3MT ERCC8 FLJ10661 MAPK3 MGAT3 NGEF PITPNM2 SF3B1 SMG6 VPS29

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	17	0.50	2.3
GTEx	Adipose Visceral Omentum	10	0.51	2.3
GTEx	Adrenal Gland	7	0.49	2.2
GTEx	Artery Aorta	14	0.49	2.3
GTEx	Artery Coronary	2	0.17	2.3
GTEx	Artery Tibial	17	0.47	2.3
GTEx	Brain Caudate basal ganglia	3	0.34	2.2
GTEx	Brain Cerebellar Hemisphere	2	0.14	2.2
GTEx	Brain Cerebellum	8	0.42	2.5
GTEx	Brain Cortex	7	0.70	2.3
GTEx	Brain Frontal Cortex BA9	2	0.22	2.4
GTEx	Brain Hippocampus	0	0.00	2.4
GTEx	Brain Hypothalamus	3	0.53	2.1
GTEx	Brain Nucleus accumbens basal ganglia	5	0.60	2.3
GTEx	Brain Putamen basal ganglia	2	0.33	2.2
GTEx	Breast Mammary Tissue	13	0.68	2.5
GTEx	Breast Mammary Tissue (Male)	6	0.53	2.4
GTEx	Breast Mammary Tissue (Female)	10	0.64	2.3
GTEx	Cells EBV-transformed lymphocytes	8	0.58	2.5
GTEx	Cells Transformed fibroblasts	22	0.54	2.4
GTEx	Colon Sigmoid	8	0.56	2.4
GTEx	Colon Transverse	10	0.50	2.5
GTEx	Esophagus Gastroesophageal Junction	7	0.50	2.4
GTEx	Esophagus Mucosa	13	0.40	2.4
GTEx	Esophagus Muscularis	19	0.61	2.3
GTEx	Heart Atrial Appendage	4	0.26	2.3
GTEx	Heart Left Ventricle	8	0.54	2.4
GTEx	Liver	4	0.57	2.4
GTEx	Lung	13	0.47	2.4
GTEx	Muscle Skeletal	8	0.28	2.3
GTEx	Nerve Tibial	19	0.45	2.3
GTEx	Ovary	3	0.34	2.4
GTEx	Pancreas	7	0.44	2.6
GTEx	Pituitary	6	0.55	2.4
GTEx	Prostate	4	0.49	2.6
GTEx	Skin Not Sun Exposed Suprapubic	10	0.42	2.3
GTEx	Skin Sun Exposed Lower leg	8	0.23	2.3
GTEx	Small Intestine Terminal Ileum	3	0.68	2.6
GTEx	Spleen	11	0.80	2.4
GTEx	Stomach	4	0.28	2.3
GTEx	Testis	23	0.75	2.5
GTEx	Thyroid	20	0.52	2.4
GTEx	Uterus	0	0.00	2.2
GTEx	Vagina	2	0.33	2.2
GTEx	Whole Blood	10	0.52	2.4
METSIM	Adipose	11	0.24	2.1
NTR	Blood	5	0.21	2.1
ROSMAP	Brain Pre-frontal Cortex	17	0.40	2.4
YFS	Blood	14	0.31	2.1
CommonMind	Brain Pre-frontal Cortex	14	0.27	2.2
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	9	0.57	2.4
The Cancer Genome Atlas	Breast Invasive Carcinoma	13	0.31	2.2
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	3	0.29	2.2
The Cancer Genome Atlas	Colon Adenocarcinoma	7	0.36	2.3
The Cancer Genome Atlas	Esophageal Carcinoma	2	0.31	2.4
The Cancer Genome Atlas	Glioblastoma Multiforme	7	0.73	2.3
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	5	0.19	2.2
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	14	0.36	2.2
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	11	0.57	2.3
The Cancer Genome Atlas	Brain Lower Grade Glioma	12	0.29	2.2
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	3	0.28	2.2
The Cancer Genome Atlas	Lung Adenocarcinoma	8	0.29	2.2
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	11	0.46	2.3
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	6	0.40	2.3
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	8	0.50	2.3
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	7	0.56	2.2
The Cancer Genome Atlas	Prostate Adenocarcinoma	13	0.30	2.2
The Cancer Genome Atlas	Rectum Adenocarcinoma	2	0.30	2.1
The Cancer Genome Atlas	Soft Tissue Sarcoma	3	0.30	2.2
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.20	2.2
The Cancer Genome Atlas	Stomach Adenocarcinoma	4	0.25	2.4
The Cancer Genome Atlas	Testicular Germ Cell Tumors	8	0.66	2.2
The Cancer Genome Atlas	Thyroid Carcinoma	23	0.47	2.3
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.00	1.9